Effect of hemodiafiltration on pregnancy-associated plasma protein A (PAPP-A) and related parameters

Renal Failure

Volumn 28, Issue 8, 2006, Pages 715-721

  Kalousová, Marta ^a   Hodková, Magdaléna ^a   Dusilová Sulková, Sylvie ^a,b   Uhrová, Jana ^a   Tesař, Vladimír ^a   Zima, Tomáš ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Hemodiafiltration; Hemodialysis; Insulin like growth factor; Matrix metalloproteinase; PAPP A; Pregnancy associated plasma protein A

Indexed keywords

GELATINASE A; GELATINASE B; POLYSULFONE; PREGNANCY ASSOCIATED PLASMA PROTEIN A; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; EVALUATION; FEMALE; HEMODIAFILTRATION; HIGH RISK POPULATION; HUMAN; MALE; OUTCOME ASSESSMENT; PARAMETER; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROIMMUNOASSAY; HEMODIAFILTRATION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4; INSULIN-LIKE GROWTH FACTOR I; KIDNEY FAILURE, CHRONIC; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PREGNANCY; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33845636390     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220600925412     Document Type: Article

References (24)

1. Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR Jr, Virmani R, Oxvig C, Schwartz RS. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 2001;345:1022-1029.
2. Lund J, Qiu-Ping Q, Ilva T, Pettersson K, Voipio-Pulkki LM, Porela P, Pulkki K. Circulating pregnancy-associated plasma protein A predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation. 2003;108:1924-1926.
3. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Simoons ML, Zeiher AM, CAPTURE Study Investigators. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol. 2005;45:229-237.
4. Cosin-Sales J, Kaski JC, Christiansen M, Kaminski P, Oxvig C, Overgaard MT, Cole D, Holt DW. Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris. Eur J Heart J. 2005;26:2093-2098.
5. Kalousova M, Sulkova S, Fialova L, Soukupova J, Malbohan IM, Spacek P, Braun M, Mikulikova L, Fortova M, Horejsi M, Tesar V, Zima T. Glycoxidation and inflammation in chronic hemodialysis patients. Nephrol Dial Transplant. 2003;18:2577-2581.
6. Fialova L, Kalousova M, Soukupova J, Sulkova S, Merta M, Jelinkova E, Horejsi M, Sramek P, Malbohan I, Mikulikova L, Tesar V, Zima T. Relationship of pregnancy-associated plasma protein A (PAPP-A) to renal function and dialysis modalities. Kidney Blood Press Res. 2004;27:88-95.
7. Kalousova M, Horejsi M, Fialova L, Soukupova J, Sulkova S, Malbohan I, Tesar V, Zima T. Increased levels of pregnancy-associated plasma protein A (PAPP-A) are associated with mortality of hemodialysis patients: preliminary results. Blood Purif. 2004;22:298-300.
8. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, Yates JR III, Conover CA. The insulin-like growth factor-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy associated plasma protein-A. Proc Natl Acad Sci. 1999;96:3149-3153.
9. Jones JI, Prevette T, Gockerman A, Clemmons DR. Ligand occupancy of the αVβ3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc Natl Acad Sci USA. 1996;96:2482-2487.
10. Renier G, Clement I, Desfaits AC, Lambert A. Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-α production. Endocrinology. 1996;137:4611-4618.
11. Katsuda S, Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Tromb. 2003;10:267-274.
12. Watanabe N, Ikeda U. Matrix metalloproteinase and atherosclerosis. Curr Atheroscler Rep. 2004;6:112-120.
13. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. Matrix metalloproteinases, inflammation and atherosclerosis: Therapeutic perspectives. Clin Chem Lab Med. 2004;42:121-131.
14. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smiega M, Hafner G, Meyer J, Cambien F, Tiret L, AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003;107:1579-1585.
15. Kalousova M, Lachmanova J, Mokrejsova M, Mikova B, Fialova L, Malbohan IM, Tesar V, Zima T. Pregnancy-associated plasma protein A during hemodialysis with polyamide and diacetate cellulosic membranes. Int J Artif Organs. 2004;27:943-948.
16. Hodkova M, Kalousova M, Dusilova-Sulkova S, Malbohan IM, Zima T. Intravenous iron gluconate administration increases circulating PAPP-A in haemodialysis patients. Ren Fail. 2005;27:707-711.
17. Davey MW, Teisner B, Sonisich M, Grudzinskas JG. Interaction between heparin and human pregnancy-associated plasma protein A (PAPP-A): a simple purification procedure. Anal Biochem.1983;131:18-24.
18. Oxvig C, Sand O, Kristensen T, Gleich GJ, Sottrup-Jensen L. Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein. J Biol Chem. 1993;268:12243-12246.
19. Qin QP, Christiansen M, Petterson K. Point-of-care time-resolved immunofluorimetric assay for human pregnancy associated plasma protein A (PAPP-A) for use in first-trimester screening for Down syndrome. Clin Chem. 2002;48:473-483.
20. Qin QP, Laitinen P, Majamaa-Voltti K, Ericksson S, Kumpula EK, Pettersson K. Release patterns of pregnancy-associated plasma protein A (PAPP-A) in patients with acute coronary syndromes. Scand Cardiovasc. J. 2002;36:358-361.
21. Vaslaki L, Major L, Berta K, Karatson A, Misz M, Pethoe F, Ladanyi E, Fodor B, Stein G, Pischetsrieder M, Zima T, Wojke R, Gauly A, Passlick-Deetjen J. On-line haemodiafiltration versus haemodialysis: stable haematocrit with less erythropoietin and improvement of other relevant blood parameters. Blood Purif. 2006;24:163-173.
22. Bohé J, Joly MO, Arkouche W, Laville M, Fouque D. Haemodialysis with biocompatible high permeability AN-69 membrane does not alter plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3. Nephrol Dial Transplant. 2001;16:590-594.
23. Ebihara I, Nakamura T, Tomino Y, Shimada N, Koide H. Metalloproteinase-9 mRNA expression in monocytes from patients with chronic renal failure. Am J Nephrol. 1998;18:305-310.
24. Nakamura T, Matsuda T, Suzuki Y, Ueda Y, Koide H. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with atherosclerosis obliterans. ASAIO J. 2003;49:430-434.